Fractyl Health Q2 net loss narrows on lower expenses
Fractyl Health Q2 net loss narrows on lower expenses
Overview
US metabolic therapeutics firm's Q2 net loss narrowed from prior year on lower operating expenses
Q2 adjusted EBITDA loss narrowed yr/yr, reflecting reduced operating expenses
Company reiterates cash runway into early 2027, beyond anticipated pivotal data readout
Outlook
Fractyl reiterates cash runway guidance into early 2027
Result Drivers
LOWER R&D SPENDING - Co said Q2 R&D expenses fell mainly due to reduced spending on Revita and Rejuva programs
NO SERIOUS ADVERSE EVENTS - Co said no device- or procedure-related serious adverse events occurred through one year in Revita studies
Company press release: ID:nGNX7WYrCk
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss |
| $25.50 mln |
|
Q2 Adjusted EBITDA |
| -$16.30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Fractyl Health, Inc. is $5.10, about 629% above its August 7 closing price of $0.70
Reuters Recommended Reads
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 10 - Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)